Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

XPH Guru Trades in

XPH Guru Trades in

Q4 2014

XPH Guru Trades in Q4 2014

Ken Fisher 3,425 sh (New)
» More
Q1 2015

XPH Guru Trades in Q1 2015

Ken Fisher Sold Out
» More

Ratios

vs
industry
vs
history
P/E(ttm) 30.40
XPH's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 30.40 )
Ranked among companies with meaningful P/E(ttm) only.
XPH' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 30.4
Current: 30.4
0
30.4
PE(NRI) 30.40
XPH's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 30.40 )
Ranked among companies with meaningful PE(NRI) only.
XPH' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 30.4
Current: 30.4
0
30.4
P/B 3.15
XPH's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 3.15 )
Ranked among companies with meaningful P/B only.
XPH' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 3.15
Current: 3.15
0
3.15

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.64
XPH's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 0.64 )
Ranked among companies with meaningful Dividend Yield only.
XPH' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.64
Current: 0.64
0
0.64
Yield on cost (5-Year) 0.64
XPH's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 0.64 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XPH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.64
Current: 0.64
0
0.64

More Statistics

Short Percentage of Float0.00%
52-Week Range $37.82 - 125.21
Shares Outstanding (Mil)17,900,000.00
» More Articles for XPH

Headlines

Articles On GuruFocus.com
2 CEOs Make Big Buys of Their Companies’ Stocks May 25 2016 
Unlike SunEdison, Canadian Solar Can Manage Its Debt May 25 2016 
Netflix: What the Numbers Say Versus What Investors Think May 25 2016 
Alan Fournier Acquires Stake in PayPal Holdings May 25 2016 
GernsteinFisher - Globalization: Past, Present, and Future May 25 2016 
Third Avenue Management Q2 2016 International Value Letter May 25 2016 
Third Avenue Management Comments on Weyerhaeuser May 25 2016 
Third Avenue Management Comments on Johnson Controls May 25 2016 
Third Avenue Management Comments on Apache May 25 2016 
Third Avenue Management Comments on Comerica May 25 2016 

More From Other Websites
Keytruda: Merck’s Immuno-Oncology Blockbuster Drug May 20 2016
Pharmaceuticals & Emerging Market: Two ETFs Trading with Outsized Volume May 20 2016
Januvia and Janumet: Merck’s Blockbuster Diabetes Drugs May 12 2016
Merck’s Valuation Cheat Sheet for Fiscal 1Q16 May 11 2016
Mudslinging Over Valeant Pharmaceuticals May 07 2016
How Eli Lilly’s Cardiovascular Franchise Performed in 1Q16 May 05 2016
Pharma ETFs Outlook -- Drug Pricing Issues Remain in Focus May 04 2016
Finding Pharmaceuticals ETFs With Rebound Potential May 04 2016
What Do Analysts Recommend for Jazz Pharmaceuticals? Apr 26 2016
Analyzing Akorn’s Strategy to Withstand Generic Industry Challenges Apr 20 2016
Is Mallinckrodt Spending Enough on R&D? Apr 11 2016
Your Horizon Breakdown: Performance across Segments Apr 06 2016
How Horizon Became a Growth Stock Mar 28 2016
Mylan Expected to Further Strengthen EpiPen Franchise in 2016 Mar 24 2016
Where Else Have We Seen Mallinckrodt’s ‘Acquire to Invest’ Strategy? Mar 23 2016
Saturday links: poised for growth Mar 12 2016
5 Best Performing Bull Run Equity ETFs Mar 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK